Published online before print December 23, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
,,,,
,
Departments of *Pharmacology, Gastroenterological Surgery, Transplant, and Surgical Oncology, and Pathology, Okayama University Graduate School of Medicine and Dentistry, Japan; and Novartis Institutes for Biomedical Research, Basel, Switzerland
A novel, proinflammatory cytokine, interleukin (IL)-18 production was detected in the medium of human monocytes treated with 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, pravastatin, and fluvastatin (0.1 and 1 µM) but not with the statin-derived lymphocyte function-associated antigen-1 (LFA-1) inhibitor LFA703, which did not inhibit HMG-CoA reductase. Pravastatin and fluvastatin also induced the production of IL-18, tumor necrosis factor 
(TNF-) and interferon-
(IFN-) in human peripheral blood mononuclear cells (PBMC) in contrast to LFA703. IL-18 production by PBMC is located upstream of the cytokine cascade activated by these statins. The IL-18-induced cytokine production was demonstrated to be dependent on adhesion molecule expression on monocytes. In the absence and presence of lower concentrations (0.1 and 1 ng/ml) of IL-18, pravastatin and fluvastatin inhibited the expression of intercellular adhesion molecule (ICAM)-1 and induced the expression of CD40, whereas LFA703 had no effect. In the presence of higher concentrations (5, 10, and 100 ng/ml) of IL-18, pravastatin, fluvastatin, and LFA703 similarly inhibited the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-, and IFN- in PBMC. The effects of pravastatin and fluvastatin but not LFA703 were abolished by the addition of mevalonate, indicating the involvement of HMG-CoA reductase in the action of pravastatin and fluvastatin. Thus, the effects of LFA703 were distinct from those of pravastatin and fluvastatin in the presence of lower concentrations of IL-18. It was concluded that LFA703 has the inhibitory effect on an IL-18-initiated immune response without any activation on monocytes.
Key Words: human • peripheral blood mononuclear cells • 3-hydroxy-3-methylglutaryl coenzyme-A
This article has been cited by other articles:
 |
|
 |
|
  R. P. Young, R. Hopkins, and T. E. Eaton Pharmacological actions of statins: potential utility in COPD Eur. Respir. Rev., December 1, 2009; 18(114): 222 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Montecucco, F. Burger, G. Pelli, N. K. Poku, C. Berlier, S. Steffens, and F. Mach Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes Rheumatology, March 1, 2009; 48(3): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Birnbaum, B. Cree, I. Altafullah, M. Zinser, and A. T. Reder Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis Neurology, October 28, 2008; 71(18): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Takahashi, G. Weitz-Schmidt, H. Iwagaki, T. Yoshino, N. Tanaka, and M. Nishibori Hypothesis: the antitumor activities of statins may be mediated by IL-18 J. Leukoc. Biol., August 1, 2006; 80(2): 215 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
